Clinical Trials | December 04, 2025
Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis
The company is excluding data from the affected sites to maintain the study's integrity
The company is excluding data from the affected sites to maintain the study's integrity
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
Germany will be the first launch market
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
Subscribe To Our Newsletter & Stay Updated
